🇺🇸 Anti Thymocyte Globulin in United States

2,092 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 418 reports (19.98%)
  2. Pyrexia — 369 reports (17.64%)
  3. Cytomegalovirus Infection — 240 reports (11.47%)
  4. Mucosal Inflammation — 164 reports (7.84%)
  5. Drug Ineffective — 161 reports (7.7%)
  6. Pneumonia — 155 reports (7.41%)
  7. Acute Graft Versus Host Disease — 154 reports (7.36%)
  8. Sepsis — 150 reports (7.17%)
  9. Transplant Rejection — 141 reports (6.74%)
  10. Post Transplant Lymphoproliferative Disorder — 140 reports (6.69%)

Source database →

Anti Thymocyte Globulin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Anti Thymocyte Globulin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Anti Thymocyte Globulin in United States?

Novartis Pharmaceuticals is the originator. The local marketing authorisation holder may differ — check the official source linked above.